Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR) announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for treating Wilson disease. The designation makes Monopar potentially eligible for a future pediatric Priority Review Voucher, which can shorten FDA review timelines or be sold to another sponsor.

Positive

• FDA Rare Pediatric Disease designation granted for ALXN1840 in Wilson disease
• ALXN1840 recognized as a late-stage candidate targeting serious pediatric condition
• Potential eligibility for a future pediatric Priority Review Voucher at NDA approval
• Priority Review Voucher could shorten FDA review time by several months
• Priority Review Voucher can be used, sold, or transferred to another sponsor

Negative

• None.

News Market Reaction – MNPR

-2.08%

7 alerts

-2.08% Session close to close

+3.6% Peak in 1 hr 34 min

$672.08M Market Cap

0.3x Rel. Volume

In the Jun 30 session, MNPR declined 2.08%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FDA Rare Pediatric Disease designation and potential PRV upside for ALX...

Analysis

This announcement highlights FDA Rare Pediatric Disease designation and potential PRV upside for ALXN1840, adding to an ongoing NDA-focused story. Investors should watch future regulatory milestones and any use of the existing shelf registration for funding.

Key Figures

Shelf registration capacity: $300,000,000 Pediatric age range: birth to 18 years

2 metrics

Shelf registration capacity $300,000,000 Maximum aggregate offering price under Form S-3 shelf

Pediatric age range birth to 18 years Age range targeted under FDA Rare Pediatric Disease designation

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Phase 2 liver data	Positive	-1.0%	Phase 2 ALXN1840 data showing liver stabilization and neurologic improvement.
May 19	Phase 2 copper data	Positive	+10.2%	Phase 2 data showing rapid, significant improvement in copper balance.
May 14	Q1 2026 earnings	Neutral	-0.7%	Q1 2026 results and confirmation of mid-2026 NDA plans for ALXN1840.
Apr 19	Phase 3 neurology data	Positive	-2.7%	Phase 3 FoCus data showing greater neurologic benefit vs standard of care.
Mar 27	FY 2025 earnings	Neutral	-0.8%	FY 2025 results, financing update, and plans for mid-2026 ALXN1840 NDA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

MNPR has frequently traded down or mixed following positive clinical and corporate updates, with only one strong upside reaction in recent months.

Key Terms

rare pediatric disease, priority review voucher, priority review, nda

4 terms

rare pediatric disease regulatory

"FDA has granted Rare Pediatric Disease (RPD) designation to ALXN1840"

A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.

priority review voucher regulatory

"potential at the time of NDA approval to receive a pediatric Priority Review Voucher (PRV)"

A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.

priority review regulatory

"Priority review can reduce the FDA’s target review time by several months"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

nda regulatory

"potential at the time of NDA approval to receive a pediatric Priority Review Voucher"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease.

The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation provides the Company with the potential at the time of NDA approval to receive a pediatric Priority Review Voucher (PRV), which can be used to obtain priority review of a subsequent marketing application or sold or transferred to another sponsor. Priority review can reduce the FDA’s target review time by several months.

“Receiving Rare Pediatric Disease designation for ALXN1840 underscores the serious impact that Wilson disease has on patients and reinforces the urgency of bringing forward a new treatment option,” said Chandler Robinson, M.D., Chief Executive Officer of Monopar.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body’s ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients. ALXN1840 is an oral tablet with a once-a-day dosing regimen.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. An example of a forward-looking statement includes the statement concerning: that the designation (RPD) provides the Company with the potential at the time of (ALXN1840) NDA approval to receive a pediatric Priority Review Voucher (PRV). The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to whether the ALXN1840 marketing application will receive marketing approval and, if approved, whether Monopar will be awarded a Priority Review Voucher; whether, if awarded, the Priority Review Voucher can be used to obtain priority review of a subsequent marketing application or sold or transferred to another sponsor; the continued authorization and availability of the Rare Pediatric Disease Priority Review Voucher program; uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:
X: @MonoparTx LinkedIn: Monopar Therapeutics

Source: Monopar Therapeutics Inc.

FAQ

What did Monopar Therapeutics (MNPR) announce about ALXN1840 on June 30, 2026?

Monopar announced that the FDA granted Rare Pediatric Disease designation to ALXN1840 for treating Wilson disease. According to Monopar, this late-stage candidate now qualifies for potential pediatric Priority Review Voucher eligibility at the time of a future NDA approval.

What is FDA Rare Pediatric Disease designation for ALXN1840 in Wilson disease?

The designation recognizes ALXN1840 as a therapy intended for a serious disease primarily affecting children. According to Monopar, the FDA’s Rare Pediatric Disease program may allow the company to receive a pediatric Priority Review Voucher if ALXN1840 ultimately obtains NDA approval.

How could FDA Rare Pediatric Disease designation benefit Monopar shareholders (MNPR)?

The designation may provide access to a pediatric Priority Review Voucher, which has potential financial and strategic value. According to Monopar, such vouchers can expedite review of another drug application or be sold or transferred to another sponsor for cash proceeds.

What is a pediatric Priority Review Voucher and how might Monopar use it?

A pediatric Priority Review Voucher allows faster FDA review of a future marketing application. According to Monopar, if earned at ALXN1840 NDA approval, the voucher could either support priority review of another product or be sold or transferred to another company.

How does FDA priority review affect ALXN1840’s potential approval timeline?

Priority review can shorten the FDA’s target review time by several months compared with standard review. According to Monopar, a pediatric Priority Review Voucher linked to ALXN1840’s success could accelerate evaluation of a subsequent Monopar marketing application, improving development and commercialization timelines.

Why is Rare Pediatric Disease designation important for Wilson disease patients and MNPR?

The designation highlights Wilson disease as a serious condition primarily impacting children and adolescents. According to Monopar, FDA recognition and potential voucher eligibility support efforts to advance ALXN1840 as a new treatment option, which may strengthen the company’s late-stage development portfolio.